SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 263 filers reported holding SAGE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 2.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,660,024 | +192.4% | 80,662 | +568.1% | 0.00% | +100.0% |
| Q2 2023 | $567,719 | -72.1% | 12,074 | -75.1% | 0.00% | -50.0% |
| Q1 2023 | $2,033,172 | +10.0% | 48,455 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $1,848,074 | -21.4% | 48,455 | -18.4% | 0.00% | -33.3% |
| Q3 2022 | $2,350,000 | +23.4% | 59,355 | +0.7% | 0.00% | +50.0% |
| Q2 2022 | $1,904,000 | -10.7% | 58,955 | -8.5% | 0.00% | 0.0% |
| Q1 2022 | $2,132,000 | +14.4% | 64,400 | +47.0% | 0.00% | 0.0% |
| Q4 2021 | $1,863,000 | -4.0% | 43,800 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $1,941,000 | +1.4% | 43,800 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,915,000 | -57.8% | 43,800 | -27.8% | 0.00% | -60.0% |
| Q1 2021 | $4,543,000 | -5.2% | 60,700 | +9.6% | 0.01% | -16.7% |
| Q4 2020 | $4,792,000 | +29.2% | 55,394 | -8.7% | 0.01% | +20.0% |
| Q3 2020 | $3,710,000 | +47.0% | 60,694 | 0.0% | 0.01% | +25.0% |
| Q2 2020 | $2,524,000 | +109.5% | 60,694 | +44.7% | 0.00% | +100.0% |
| Q1 2020 | $1,205,000 | -84.3% | 41,946 | -60.5% | 0.00% | -81.8% |
| Q4 2019 | $7,668,000 | -63.8% | 106,213 | -29.7% | 0.01% | -65.6% |
| Q3 2019 | $21,186,000 | -28.8% | 151,013 | -7.1% | 0.03% | -28.9% |
| Q2 2019 | $29,755,000 | +13.0% | 162,513 | -1.9% | 0.04% | +12.5% |
| Q1 2019 | $26,341,000 | +73.2% | 165,613 | +4.3% | 0.04% | +53.8% |
| Q4 2018 | $15,205,000 | -30.6% | 158,729 | +2.4% | 0.03% | -18.8% |
| Q3 2018 | $21,902,000 | -1.1% | 155,060 | +9.6% | 0.03% | -5.9% |
| Q2 2018 | $22,148,000 | +4.3% | 141,494 | +7.3% | 0.03% | +3.0% |
| Q1 2018 | $21,242,000 | +13.0% | 131,883 | +15.5% | 0.03% | +22.2% |
| Q4 2017 | $18,801,000 | +259.6% | 114,147 | +36.0% | 0.03% | +237.5% |
| Q3 2017 | $5,228,000 | -14.3% | 83,918 | +9.5% | 0.01% | -20.0% |
| Q2 2017 | $6,103,000 | +17.6% | 76,630 | +4.9% | 0.01% | +25.0% |
| Q1 2017 | $5,190,000 | +69.1% | 73,030 | +21.5% | 0.01% | +60.0% |
| Q4 2016 | $3,069,000 | +87.8% | 60,109 | +69.4% | 0.01% | +66.7% |
| Q3 2016 | $1,634,000 | – | 35,482 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 475,600 | $15,362,000 | 5.31% |
| Integral Health Asset Management, LLC | 412,257 | $13,316,000 | 2.74% |
| Palo Alto Investors LP | 851,409 | $27,501,000 | 2.40% |
| Boxer Capital, LLC | 1,094,000 | $35,336,000 | 2.24% |
| DAFNA Capital Management LLC | 180,306 | $5,824,000 | 1.59% |
| Ikarian Capital, LLC | 250,000 | $8,075,000 | 1.47% |
| Bellevue Group AG | 2,973,178 | $96,034,000 | 1.36% |
| SECTOR GAMMA AS | 118,476 | $3,827,000 | 0.86% |
| Artal Group S.A. | 450,000 | $14,535,000 | 0.78% |
| Diametric Capital, LP | 19,393 | $626,000 | 0.46% |